Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
ACS Chem Neurosci ; 11(17): 2602-2614, 2020 09 02.
Artigo em Inglês | MEDLINE | ID: mdl-32697906

RESUMO

Studies in mouse, and to a lesser extent in rat, have revealed the neuroanatomical distribution of vesicular glutamate transporters (VGLUTs) and begun exposing the critical role of VGLUT2 and VGLUT3 in pain transmission. In the present study in rat, we used specific riboprobes to characterize the transcript expression of all three VGLUTs in lumbar dorsal root ganglia (DRGs) and in the thoracolumbar, lumbar, and sacral spinal cord. We show for the first time in rat a very discrete VGLUT3 expression in DRGs and in deep layers of the dorsal horn. We confirm the abundant expression of VGLUT2, in both DRGs and the spinal cord, including presumable motorneurons in the latter. As expected, VGLUT1 was present in many DRG neuron profiles, and in the spinal cord it was mostly localized to neurons in the dorsal nucleus of Clarke. In rats with a 10 day long hindpaw inflammation, increased spinal expression of VGLUT2 transcript was detected by qRT-PCR, and intrathecal administration of the nonselective VGLUT inhibitor Chicago Sky Blue 6B resulted in reduced mechanical and thermal allodynia for up to 24 h. In conclusion, our results provide a collective characterization of VGLUTs in rat DRGs and the spinal cord, demonstrate increased spinal expression of VGLUT2 during chronic peripheral inflammation, and support the use of spinal VGLUT blockade as a strategy for attenuating inflammatory pain.


Assuntos
Gânglios Espinais , Proteínas Vesiculares de Transporte de Glutamato , Animais , Inflamação , Camundongos , Neurônios , Ratos , Medula Espinal , Proteína Vesicular 1 de Transporte de Glutamato/genética , Proteína Vesicular 2 de Transporte de Glutamato/genética , Proteínas Vesiculares de Transporte de Glutamato/genética
2.
Epilepsia ; 61(8): 1581-1594, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32662890

RESUMO

OBJECTIVE: Drebrins are crucial for synaptic function and dendritic spine development, remodeling, and maintenance. In temporal lobe epilepsy (TLE) patients, a significant hippocampal synaptic reorganization occurs, and synaptic reorganization has been associated with hippocampal hyperexcitability. This study aimed to evaluate, in TLE patients, the hippocampal expression of drebrin using immunohistochemistry with DAS2 or M2F6 antibodies that recognize adult (drebrin A) or adult and embryonic (pan-drebrin) isoforms, respectively. METHODS: Hippocampal sections from drug-resistant TLE patients with hippocampal sclerosis (HS; TLE, n = 33), of whom 31 presented with type 1 HS and two with type 2 HS, and autopsy control cases (n = 20) were assayed by immunohistochemistry and evaluated for neuron density, and drebrin A and pan-drebrin expression. Double-labeling immunofluorescences were performed to localize drebrin A-positive spines in dendrites (MAP2), and to evaluate whether drebrin colocalizes with inhibitory (GAD65) and excitatory (VGlut1) presynaptic markers. RESULTS: Compared to controls, TLE patients had increased pan-drebrin in all hippocampal subfields and increased drebrin A-immunopositive area in all hippocampal subfields but CA1. Drebrin-positive spine density followed the same pattern as total drebrin quantification. Confocal microscopy indicated juxtaposition of drebrin-positive spines with VGlut1-positive puncta, but not with GAD65-positive puncta. Drebrin expression in the dentate gyrus of TLE cases was associated negatively with seizure frequency and positively with verbal memory. TLE patients with lower drebrin-immunopositive area in inner molecular layer (IML) than in outer molecular layer (OML) had a lower seizure frequency than those with higher or comparable drebrin-immunopositive area in IML compared with OML. SIGNIFICANCE: Our results suggest that changes in drebrin-positive spines and drebrin expression in the dentate gyrus of TLE patients are associated with lower seizure frequency, more preserved verbal memory, and a better postsurgical outcome.


Assuntos
Epilepsia Resistente a Medicamentos/metabolismo , Epilepsia do Lobo Temporal/metabolismo , Hipocampo/metabolismo , Neuropeptídeos/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Lobectomia Temporal Anterior , Região CA1 Hipocampal/metabolismo , Região CA2 Hipocampal/metabolismo , Região CA3 Hipocampal/metabolismo , Estudos de Casos e Controles , Dendritos/metabolismo , Dendritos/patologia , Giro Denteado/metabolismo , Epilepsia Resistente a Medicamentos/patologia , Epilepsia Resistente a Medicamentos/cirurgia , Epilepsia do Lobo Temporal/patologia , Epilepsia do Lobo Temporal/cirurgia , Feminino , Glutamato Descarboxilase/metabolismo , Hipocampo/patologia , Hipocampo/cirurgia , Humanos , Imuno-Histoquímica , Masculino , Microscopia Confocal , Proteínas Associadas aos Microtúbulos/metabolismo , Pessoa de Meia-Idade , Plasticidade Neuronal , Esclerose , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo
3.
Neurosci Lett ; 694: 116-123, 2019 02 16.
Artigo em Inglês | MEDLINE | ID: mdl-30500398

RESUMO

Neuroprotective effects of short prolactin (PRL) pre-treatment against kainic acid (KA)-induced damage include neuron loss avoidance in all hippocampal regions and attenuation of seizures. Recent evidence points PRL receptor (PRL-R) as mediator of such neuroprotective effects and seizures as regulators of neuronal marker transcript expression in the hippocampus. Here, we investigated if a daily PRL dose of 100 µg or vehicle for 14 days in ovariectomized rats (OVX) prevents neuron loss induced by KA administered on the third day of PRL treatment in a systemic single dose of 7.5 mg/kg or vehicle, and promotes PRL-R, vesicular glutamate transporter 1 (VGLUT1) and glutamic acid decarboxylase 65 (GAD65) expression changes in the hippocampus of sacrificed rats 27 days after the KA administration. Immunostaining for Neu-N and PRL-R revealed significant neuron number and PRL-R expression reduction induced by KA that was prevented and turned into overexpression respectively in all hippocampal regions when PRL was added; while VGLUT1,and GAD65 immunostaining displayed expression decrease in the CA1 of injured rats, prevented in the last case and turned into VGLUT1, overexpression when administered PRL. These data indicate that chronic PRL administration before damage induces hippocampal neuroprotection associated with PRL-R and VGLUT1 overexpression, the latter in a regiondependent way.


Assuntos
Hipocampo/efeitos dos fármacos , Ácido Caínico/toxicidade , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/administração & dosagem , Prolactina/administração & dosagem , Receptores da Prolactina/metabolismo , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo , Animais , Agonistas de Aminoácidos Excitatórios/toxicidade , Feminino , Glutamato Descarboxilase/metabolismo , Hipocampo/metabolismo , Hipocampo/patologia , Neurônios/metabolismo , Ratos
4.
J Neurosci Res ; 97(4): 520-534, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30549080

RESUMO

Astrogliosis and microglial reactions are correlated with the formation of scar tissue and synapse loss. 4-hydroxy-tempo (TEMPOL) is a reactive oxygen species scavenger with proven neuroprotective efficacy in experimental models of traumatic injury and cerebral ischemia. TEMPOL has not, however, been applied following ventral root lesions, which are particularly correlated with the degeneration of spinal motoneurons following brachial plexus injuries. Thus, the present study investigated the effects of TEMPOL on motoneurons and adjacent glial reactions, with a particular focus on the preservation of excitatory and inhibitory spinal circuits. Adult female Sprague Dawley rats were subjected to ventral root crush (VRC) at the lumbar intumescence. Animals were divided into the following experimental groups: (a) VRC-saline treatment; (b) VRC-TEMPOL treatment (12 mg/kg, n = 5), and (c) VRC-TEMPOL treatment (250 mg/kg, n = 5). The spinal cord tissue located contralateral to the lesion was used as the control. Fourteen days after lesioning, the rats were euthanized and the spinal cords were removed for motoneuron counting and immunolabeling with glial (GFAP and Iba-1) and synapse markers (synaptophysin, VGLUT-1, and GAD65). Although TEMPOL did not exert neuroprotective effects at the studied concentrations, the modulation of glial reactions was significant at higher doses. Thus, synaptophysin staining was preserved and, in particular, VGLUT-1-positive inputs were maintained, thereby indicating that TEMPOL preserved proprioceptive glutamatergic inputs without exacerbating the rate of motoneuron degeneration. Consequently, its administration with other efficient neuroprotective substances may significantly improve the outcomes following spinal cord lesioning.


Assuntos
Óxidos N-Cíclicos/farmacologia , Hidroxilamina/farmacologia , Neuroglia/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Raízes Nervosas Espinhais/lesões , Raízes Nervosas Espinhais/metabolismo , Sinapses/efeitos dos fármacos , Animais , Antioxidantes , Feminino , Proteína Glial Fibrilar Ácida/metabolismo , Gliose , Neurônios Motores/patologia , Ratos , Ratos Sprague-Dawley , Corno Lateral da Medula Espinal/metabolismo , Raízes Nervosas Espinhais/patologia , Sinaptofisina/metabolismo , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo
5.
Neurotox Res ; 33(3): 569-579, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29297151

RESUMO

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by beta-amyloid (Aß) accumulation and neurofibrillary tangles formation in the brain which are associated to synaptic deficits and dementia. Liver X receptor (LXR) agonists have been demonstrated to revert of pathologic and cognitive defects in murine models of AD through the regulation of Apolipoprotein E, ATP-Binding Cassette A1 (ABCA1), by dampening neuroinflammation and also by reducing the levels of amyloid-ß (Aß) accumulation in the brain. However, the role of LXR with regard to the regulation of synaptic function remains relatively understudied. In the present paper, we analyzed the in-vitro effect of the LXR agonist GW3965 on synaptic function upon exposure of primary hippocampal cultures to oligomeric amyloid-ß (oAß(1-42)). We showed that oAß(1-42) exposure significantly decreased the density of mature (mushroom shaped) dendritic spines density and synaptic contacts number. oAß(1-42) also modulates the expression of pre- (VGlut1, SYT1, SV2A) and post-synaptic (SHANK2, NMDA) proteins, it decreases the expression of PINK1, and increases ROCKII, and activates of caspase-3; these changes were prevented by the pre-treating neuronal cultures with GW3965. These results show further support the role of the LXR agonist GW3965 in synaptic physiology and highlight its potential as an alternative pharmacological strategy for AD.


Assuntos
Peptídeos beta-Amiloides/farmacologia , Benzoatos/farmacologia , Benzilaminas/farmacologia , Hipocampo/citologia , Neurônios/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Sinapses/efeitos dos fármacos , Animais , Células Cultivadas , Espinhas Dendríticas/efeitos dos fármacos , Espinhas Dendríticas/metabolismo , Embrião de Mamíferos , Regulação da Expressão Gênica/efeitos dos fármacos , L-Lactato Desidrogenase/metabolismo , Receptores X do Fígado/agonistas , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Proteínas do Tecido Nervoso/metabolismo , Neurônios/citologia , Proteínas Quinases/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Sinapses/metabolismo , Sinaptotagmina I/metabolismo , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo , Quinases Associadas a rho/metabolismo
6.
Brain Struct Funct ; 221(4): 1985-2004, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-25749859

RESUMO

Using immunohistochemical techniques, we characterized changes in the expression of several neurochemical markers in lumbar 4-sacral 2 (L4-S2) dorsal root ganglion (DRG) neuron profiles (NPs) and the spinal cord of BALB/c mice after axotomy of the L6 and S1 spinal nerves, major tributaries of the pelvic (targeting pelvic visceral organs) and pudendal (targeting perineum and genitalia) nerves. Sham animals were included. Expression of cyclic AMP-dependent transcription factor 3 (ATF3), calcitonin gene-related peptide (CGRP), transient receptor potential cation channel subfamily V, member 1 (TRPV1), tyrosine hydroxylase (TH) and vesicular glutamate transporters (VGLUT) types 1 and -2 was analysed seven days after injury. L6-S1 axotomy induced dramatic de novo expression of ATF3 in many L6-S1 DRG NPs, and parallel significant downregulations in the percentage of CGRP-, TRPV1-, TH- and VGLUT2-immunoreactive (IR) DRG NPs, as compared to their expression in uninjured DRGs (contralateral L6-S1-AXO; sham mice); VGLUT1 expression remained unaltered. Sham L6-S1 DRGs only showed a small ipsilateral increase in ATF3-IR NPs (other markers were unchanged). L6-S1-AXO induced de novo expression of ATF3 in several lumbosacral spinal cord motoneurons and parasympathetic preganglionic neurons; in sham mice the effect was limited to a few motoneurons. Finally, a moderate decrease in CGRP- and TRPV1-like-immunoreactivities was observed in the ipsilateral superficial dorsal horn neuropil. In conclusion, injury of a mixed visceral/non-visceral nerve leads to considerable neurochemical alterations in DRGs matched, to some extent, in the spinal cord. Changes in these and potentially other nociception-related molecules could contribute to pain due to injury of nerves in the abdominopelvic cavity.


Assuntos
Gânglios Espinais/metabolismo , Neurônios/metabolismo , Nervo Pudendo/metabolismo , Medula Espinal/metabolismo , Fator 3 Ativador da Transcrição/metabolismo , Animais , Axotomia , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Regulação para Baixo , Genitália/inervação , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Neurônios Motores/metabolismo , Pelve/inervação , Períneo/inervação , Canais de Cátion TRPV/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismo , Regulação para Cima , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo , Proteína Vesicular 2 de Transporte de Glutamato/metabolismo
7.
Neuroscience ; 248: 95-111, 2013 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-23727452

RESUMO

Using specific riboprobes, we characterized the expression of vesicular glutamate transporter (VGLUT)1-VGLUT3 transcripts in lumbar 4-5 (L4-5) dorsal root ganglions (DRGs) and the thoracolumbar to lumbosacral spinal cord in male BALB/c mice after a 1- or 3-day hindpaw inflammation, or a 7-day sciatic nerve axotomy. Sham animals were also included. In sham and contralateral L4-5 DRGs of injured mice, VGLUT1-, VGLUT2- and VGLUT3 mRNAs were expressed in ∼45%, ∼69% or ∼17% of neuron profiles (NPs), respectively. VGLUT1 was expressed in large and medium-sized NPs, VGLUT2 in NPs of all sizes, and VGLUT3 in small and medium-sized NPs. In the spinal cord, VGLUT1 was restricted to a number of NPs at thoracolumbar and lumbar segments, in what appears to be the dorsal nucleus of Clarke, and in mid laminae III-IV. In contrast, VGLUT2 was present in numerous NPs at all analyzed spinal segments, except the lateral aspects of the ventral horns, especially at the lumbar enlargement, where it was virtually absent. VGLUT3 was detected in a discrete number of NPs in laminae III-IV of the dorsal horn. Axotomy resulted in a moderate decrease in the number of DRG NPs expressing VGLUT3, whereas VGLUT1 and VGLUT2 were unaffected. Likewise, the percentage of NPs expressing VGLUT transcripts remained unaltered after hindpaw inflammation, both in DRGs and the spinal cord. Altogether, these results confirm previous descriptions on VGLUTs expression in adult mice DRGs, with the exception of VGLUT1, whose protein expression was detected in a lower percentage of mouse DRG NPs. A detailed account on the location of neurons expressing VGLUTs transcripts in the adult mouse spinal cord is also presented. Finally, the lack of change in the number of neurons expressing VGLUT1 and VGLUT2 transcripts after axotomy, as compared to data on protein expression, suggests translational rather than transcriptional regulation of VGLUTs after injury.


Assuntos
Gânglios Espinais/metabolismo , Neurônios/metabolismo , Medula Espinal/metabolismo , Proteínas Vesiculares de Transporte de Glutamato/metabolismo , Sistemas de Transporte de Aminoácidos Acídicos/análise , Sistemas de Transporte de Aminoácidos Acídicos/metabolismo , Animais , Axotomia , Membro Posterior , Inflamação/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , RNA Mensageiro/metabolismo , Nervo Isquiático/lesões , Proteína Vesicular 1 de Transporte de Glutamato/análise , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo , Proteína Vesicular 2 de Transporte de Glutamato/análise , Proteína Vesicular 2 de Transporte de Glutamato/metabolismo , Proteínas Vesiculares de Transporte de Glutamato/análise
8.
Psicofarmacologia (B. Aires) ; 12(72): 29-37, feb. 2012. ilus
Artigo em Espanhol | BINACIS | ID: bin-129477

RESUMO

El glutamato, principal neurotransmisor excitatorio, está involucrado en mecanismos de plasticidad sináptica, memoria y muerte neuronal o glial, y el adecuado mantenimiento de sus niveles extracelulares es esencial para evitar la excitotoxicidad. En los últimos años se han producido muchos avances en el estudio de los transportadores de glutamato (VGLUTs y EAATs) encargados de su re-captura en las sinapsis. Haremos una revisión bibliográfica de sus propiedades, alteraciones producidas por su disfunción y posibles alternativas de neuroprotección. Así mismo revisaremos otro aspecto importante, la liberación de glutamato por los astrocitos bajo diversas situaciones patológicas, descubrimiento este de las últimas décadas de investigación sobre la glia (AU)


Glutamate, the major excitatory neurotransmitter, is involved in synaptic plasticity, memory and neuronal or glial death, and it is essential to proper maintenance of extracellular levels to prevent excitotoxicity. In recent years there have been many advances in the study of glutamate transporters (EAATs and VGLUTs) responsable for its re-capture at synapses. We will do a bibliographic review of their properties, changes caused by their dysfunction and possible alternatives for neuroprotection. We will also review antoher important aspect, the release of glutamate by astrocytes under different pathological conditions, discovered on the last decades by the research on glia (AU)


Assuntos
Humanos , Glutamatos , Receptores de Glutamato , Neurotransmissores , Proteínas de Transporte de Glutamato da Membrana Plasmática/deficiência , Proteínas Vesiculares de Transporte de Glutamato , Proteína Vesicular 1 de Transporte de Glutamato , Proteína Vesicular 2 de Transporte de Glutamato , Fármacos Atuantes sobre Aminoácidos Excitatórios , Astrócitos/patologia
9.
Psicofarmacologia (B. Aires) ; 12(72): 29-37, feb. 2012. ilus
Artigo em Espanhol | BINACIS | ID: bin-127653

RESUMO

El glutamato, principal neurotransmisor excitatorio, está involucrado en mecanismos de plasticidad sináptica, memoria y muerte neuronal o glial, y el adecuado mantenimiento de sus niveles extracelulares es esencial para evitar la excitotoxicidad. En los últimos años se han producido muchos avances en el estudio de los transportadores de glutamato (VGLUTs y EAATs) encargados de su re-captura en las sinapsis. Haremos una revisión bibliográfica de sus propiedades, alteraciones producidas por su disfunción y posibles alternativas de neuroprotección. Así mismo revisaremos otro aspecto importante, la liberación de glutamato por los astrocitos bajo diversas situaciones patológicas, descubrimiento este de las últimas décadas de investigación sobre la glia (AU)


Glutamate, the major excitatory neurotransmitter, is involved in synaptic plasticity, memory and neuronal or glial death, and it is essential to proper maintenance of extracellular levels to prevent excitotoxicity. In recent years there have been many advances in the study of glutamate transporters (EAATs and VGLUTs) responsable for its re-capture at synapses. We will do a bibliographic review of their properties, changes caused by their dysfunction and possible alternatives for neuroprotection. We will also review antoher important aspect, the release of glutamate by astrocytes under different pathological conditions, discovered on the last decades by the research on glia (AU)


Assuntos
Humanos , Glutamatos , Receptores de Glutamato , Neurotransmissores , Proteínas de Transporte de Glutamato da Membrana Plasmática/deficiência , Proteínas Vesiculares de Transporte de Glutamato , Proteína Vesicular 1 de Transporte de Glutamato , Proteína Vesicular 2 de Transporte de Glutamato , Fármacos Atuantes sobre Aminoácidos Excitatórios , Astrócitos/patologia
10.
Psicofarmacologia (B. Aires) ; 12(72): 29-37, feb. 2012. ilus
Artigo em Espanhol | LILACS | ID: lil-648826

RESUMO

El glutamato, principal neurotransmisor excitatorio, está involucrado en mecanismos de plasticidad sináptica, memoria y muerte neuronal o glial, y el adecuado mantenimiento de sus niveles extracelulares es esencial para evitar la excitotoxicidad. En los últimos años se han producido muchos avances en el estudio de los transportadores de glutamato (VGLUTs y EAATs) encargados de su re-captura en las sinapsis. Haremos una revisión bibliográfica de sus propiedades, alteraciones producidas por su disfunción y posibles alternativas de neuroprotección. Así mismo revisaremos otro aspecto importante, la liberación de glutamato por los astrocitos bajo diversas situaciones patológicas, descubrimiento este de las últimas décadas de investigación sobre la glia


Glutamate, the major excitatory neurotransmitter, is involved in synaptic plasticity, memory and neuronal or glial death, and it is essential to proper maintenance of extracellular levels to prevent excitotoxicity. In recent years there have been many advances in the study of glutamate transporters (EAATs and VGLUTs) responsable for its re-capture at synapses. We will do a bibliographic review of their properties, changes caused by their dysfunction and possible alternatives for neuroprotection. We will also review antoher important aspect, the release of glutamate by astrocytes under different pathological conditions, discovered on the last decades by the research on glia


Assuntos
Humanos , Astrócitos/patologia , Fármacos Atuantes sobre Aminoácidos Excitatórios , Proteínas de Transporte de Glutamato da Membrana Plasmática , Glutamatos , Neurotransmissores , Receptores de Glutamato , Proteína Vesicular 1 de Transporte de Glutamato , Proteínas Vesiculares de Transporte de Glutamato
11.
J Neurosci ; 25(30): 6939-46, 2005 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-16049169

RESUMO

Certain neurons choose the neurotransmitter they use in an activity-dependent manner, and trophic factors are involved in this phenotypic differentiation during development. Developing hippocampal granule cells (GCs) constitutively express the markers of the glutamatergic and GABAergic phenotypes, but when development is completed, the GABAergic phenotype shuts off. With electrophysiological, single-cell reverse transcription-PCR and immunohistological techniques, we show here that short-term (24 h) cultures of fully differentiated adult glutamatergic GCs, which express glutamate, VGlut-1 (vesicular glutamate transporter) mRNA, calbindin, and dynorphin mRNA, can be induced to reexpress the GABAergic markers GABA, GAD67 (glutamate decarboxylase 67 kDa isoform), and VGAT (vesicular GABA transporter) mRNA, by sustained synaptic or direct activation of glutamate receptors and by activation of TrkB (tyrosine receptor kinase B) receptors, with brain-derived neurotrophic factor (BDNF) (30 min). The expression of the GABAergic markers was prevented by the blockade of glutamate receptors and sodium or calcium channels, and by inhibitors of protein kinases and protein synthesis. In hippocampal slices of epileptic rats and in BDNF-treated slices from naive rats, we confirmed the appearance of monosynaptic GABAA receptor-mediated responses to GC stimulation, in the presence of glutamate receptors blockers. Accordingly, GC cultures prepared from these slices showed the coexpression of the glutamatergic and GABAergic markers. Our results demonstrate that the neurotransmitter choice of the GCs, which are unique in terms of their continuing birth and death throughout life, depends on programmed and environmental factors, and this process is neither limited by a critical developmental period nor restricted by their insertion in their natural network.


Assuntos
Hipocampo/citologia , Hipocampo/fisiologia , Plasticidade Neuronal/fisiologia , Animais , Fator Neurotrófico Derivado do Encéfalo/farmacologia , Calbindinas , Células Cultivadas , Dinorfinas/genética , Agonistas de Aminoácidos Excitatórios/farmacologia , Antagonistas de Aminoácidos Excitatórios/farmacologia , Ácido Glutâmico/metabolismo , Ácido Caínico/farmacologia , Plasticidade Neuronal/efeitos dos fármacos , Técnicas de Cultura de Órgãos , Fenótipo , Quinoxalinas/farmacologia , RNA Mensageiro/análise , Ratos , Ratos Wistar , Receptores de GABA/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteína G de Ligação ao Cálcio S100/metabolismo , Sinapses/fisiologia , Proteína Vesicular 1 de Transporte de Glutamato/genética , Proteínas Vesiculares de Transporte de Aminoácidos Inibidores/genética , Ácido gama-Aminobutírico/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA